Tokyo, Nov. 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059800) titled 'Multicenter observational study evaluating minimal residual disease in adult acute myeloid leukemia treatment -FBMTG AML-MRD-' on Nov. 17.
Study Type:
Observational
Primary Sponsor:
Institute - Kyushu University
Condition:
Condition - Acute Myeloid Leukemia
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - In this study, MRD measurements will be performed at the time of initial onset, after completion of each regimen or after completion of chemotherapy, and before allogeneic hematopoietic stem cell transplantation, to verify the significance of MRD measurements in AML treatment.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - 1) AML patients aged 18 to 85 years at the time of consent
2) Patients undergoing initial treatment who have not received chemotherapy or radiation therapy
3) AML patients morphologically diagnosed as AML M0, 1, 2, 4, 5, 6, or 7
4) Patients who have provided written informed consent for this study after receiving an explanation.
Key exclusion criteria - Cases that the attending physician judged to be inappropriate
Target Size - 300
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 06 Month 01 Day
Date of IRB - 2025 Year 07 Month 16 Day
Anticipated trial start date - 2025 Year 11 Month 01 Day
Last follow-up date - 2035 Year 10 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068375
Disclaimer: Curated by HT Syndication.
